[A25-32 ] Nemolizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2025
Project no.:
A25-32
Commission:
Commission awarded on 17.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-32
| Project no. | Title | Status |
|---|---|---|
| A25-31 | Nemolizumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V | Commission completed |